Galapagos NV
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
18 mrt 2014 - 07:30
Statutaire naam
Galapagos NV
Titel
Galapagos to present favorable pre-clinical data on GLPG1790, a selective ephrin receptor kinase inhibitor, at AACR in San Diego
Bericht
- First selective small molecule ephrin receptor kinase inhibitor to enter development
- GLPG1790 has high efficacy against triple-negative breast cancer
- Potentially suitable for other ephrin-driven cancers
- GLPG1790 is fully proprietary to Galapagos
Datum laatste update: 18 december 2025